Patents by Inventor Alasdair Roderick Maclean

Alasdair Roderick Maclean has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of Melanoma Using HSV Mutant
    Publication number: 20120141418
    Abstract: Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the ?34.5 gene in the long repeat region (RL) such that the ?34.5 gene is a non-functional, manufacture of medicaments and methods of testing cancer in mammals employing HSV mutant.
    Type: Application
    Filed: November 28, 2011
    Publication date: June 7, 2012
    Applicants: THE WISTAR INSTITUTE, Virttu Biologics Limited
    Inventors: Alasdair Roderick MacLean, Susanne Moira Brown, Nigel William Fraser, Bruce Paul Randazzo
  • Treatment of melanoma using HSV mutant
    Patent number: 8067012
    Abstract: Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the ?34.5 gene in the long repeat region (RL) such that the ?34.5 gene is a non-functional, manufacture of medicaments and methods of testing cancer in mammals employing HSV mutant.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: November 29, 2011
    Assignees: Crusade Laboratories Limited, The Wistar Institute
    Inventors: Alasdair Roderick MacLean, Susanne Moira Brown, Nigel William Fraser, Bruce Paul Randazzo
  • Treatment of Cancer Using HSV Mutant
    Publication number: 20100172872
    Abstract: Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the ?34.5 gene in the long repeat region (RL) such that the ?34.5 gene is a non-functional, manufacture of medicaments and methods of testing cancer in mammals employing HSV mutant.
    Type: Application
    Filed: January 22, 2010
    Publication date: July 8, 2010
    Applicants: CRUSADE LABORATORIES LIMITED, THE WISTAR INSTITUTE
    Inventors: Alasdair Roderick MacLean, Susanne Moira Brown, Nigel William Fraser, Bruce Paul Randazzo
  • Treatment of cancer using HSV mutant
    Patent number: 7674468
    Abstract: Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the ?34.5 gene in the long repeat region (RL) such that the ?34.5 gene is a non-functional, manufacture of medicaments and methods of testing cancer in mammals employing HSV mutant.
    Type: Grant
    Filed: June 13, 2005
    Date of Patent: March 9, 2010
    Assignees: Crusade Laboratories Limited, The Wistar Institute
    Inventors: Alasdair Roderick MacLean, Susanne Moira Brown, Nigel William Fraser, Bruce Paul Randazzo
  • Herpes zinc finger motifs
    Patent number: 6946253
    Abstract: The present invention relates to a method for detecting an agent for use in the treatment of herpes virus infection and use of known agents, such as 2,2?-dithiobisbenzamide (DIBA) and azodicarbonamide (ADA), and unknown agents, which selectively eject zinc bound to a zinc finger protein, for the manufacture of a medicament for the treatment of herpesvirus infections.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: September 20, 2005
    Assignee: University Court of the University of Glasgow
    Inventors: John Barklie Clements, Alasdair Roderick Maclean
  • Herpes zinc finger motifs
    Publication number: 20030186283
    Abstract: The present invention relates to a method for detecting an agent for use in the treatment of herpes virus infection and use of known agents, such as 2,2′-dithiobisbenzamide (DIBA) and azodicarbonamide (ADA), and unknown agents, which selectively eject zinc bound to a zinc finger protein, for the manufacture of a medicament for the treatment of herpesvirus infections.
    Type: Application
    Filed: February 11, 2003
    Publication date: October 2, 2003
    Inventors: John Barklie Clements, Alasdair Roderick Maclean
  • HSV strain lacking functional ICP27 and ICP34.5 genes
    Patent number: 6248320
    Abstract: The present invention provides a herpes simplex virus strain which lacks a functional ICP34.5 gene and a functional ICP27 gene. It also provides the use of a herpes simplex virus strain which lacks a functional ICP34.5 gene and a functional ICP27 gene in the treatment of disorders of, or injuries to, the nervous system of a mammal.
    Type: Grant
    Filed: June 10, 1999
    Date of Patent: June 19, 2001
    Assignees: University College London, The University Court of the University of Glasgow
    Inventors: Robert Stuart Coffin, David Seymour Latchman, Alasdair Roderick Maclean, Suzanne Moira Brown
  • Herpes simplex virus-1 deletion variants and vaccines thereof
    Patent number: 6040169
    Abstract: Novel Herpes simplex viruses and vaccines based on such novel HSV-1 strains are described. In particular, viruses having a deletion in the terminal portion of R.sub.L are provided. The virus can be further modified to express heterologous antigens and also engineered to overproduce HSV Light particles. This is achieved by incorporating a ts mutation into the UL26 gene.
    Type: Grant
    Filed: December 13, 1996
    Date of Patent: March 21, 2000
    Assignee: Medical Research Council
    Inventors: Susanne Moira Brown, Alasdair Roderick MacLean